James R. Tobin has been at the helm of 5 different companies. Mr. Tobin is Chairman for TransMedics Group, Inc. and Chairman at TransMedics, Inc. (a subsidiary of TransMedics Group, Inc.). He has been on the board of over 20 companies, currently serving on the boards of Globus Medical, Oxford Immunotec and TransMedics.
Mr.Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served as the President and CEO of Biogen, Inc., from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997. Mr. Tobin also worked at Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. Mr. Tobin also currently serves on the board of directors of Oxford Immunotech Global PLC (NYSE: OXFD), a global diagnostics company, Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics and two private companies, TransMedics, Inc., and Resolys Bio, Inc.
He served as a Lieutenant in the U.S. Navy from 1968 to 1972. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College. He is well qualified to serve on our board of directors and on our Audit Committee and Nominating and Corporate Governance Committee for numerous reasons, including his decades of experience as a senior executive of large multinational healthcare and medical device companies, and his service as a director of Boston Scientific Corporation.
Robert S. Langer, ScD, is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written more than 1,500 articles, which have been cited more than 340,000 times; his h-index of 286 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have been licensed or sublicensed to more than 400 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 35 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.
Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and in Applied Biology from MIT, a Master of Science degree in Electrical Engineering and Computer Sciences from MIT, a Ph.D. in Medical Engineering and Medical Physics from MIT, and an M.D. degree from Harvard Medical School. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems. After internal medicine training and clinical fellowship in Cardiovascular Medicine at the BWH he spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair. Many of his findings have been or are now in clinical trial validation. More than 300 students and postdoctoral fellows have passed through Dr. Edelman’s laboratory enabling publication of more than 680 original scientific articles and some 80 patents.
Dr. Edelman is a fellow of the American College of Cardiology, the American Heart Association, the Association of University Cardiologists, the American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, the American Academy of Arts and Sciences, National Academy of Inventors, the National Academy of Medicine, and the National Academy of Engineering.
Mark Stautberg has more than 35 years of medical device Sales & Marketing experience, most notably at Boston Scientific as the Senior Vice President, Sales for the Cardiovascular businesses. As SVP from 1998-2004, he grew sales ten-fold & led the launch of the TAXUS Drug Eluting Stent to unprecedented adoption, market share, revenue & speed. During Mark’s entire fourteen plus years at Scimed/Boston Scientific, he held key roles that led to their position as the leading company in Interventional Cardiology. Prior to Boston Scientific, Mark had roles of increasing responsibility at Baxter International, including Director of Marketing for the Hospital Supply Division. He also served on numerous medical device company Boards, both private & public, where he mentored commercial teams to success. Mark has a BBA in Marketing from the University of Cincinnati.
Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.
David J. Bearss, Ph.D is an experienced entrepreneur and drug developer. Dr. Bearss has a consistent and successful track record of drug discovery and development that spans the last 20 years in both academic and industrial settings. He is an expert in small molecule drug development and in the use of genetic model systems in drug discovery. He has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. Dr. Bearss has been involved in the discovery of 15 compounds that have transitioned to INDs and moved forward in clinical development. He has been a co-founder of 5 biotech companies and has been an active scientific advisor to several others. Dr. Bearss served as Chief Scientific Officer at Montigen Pharmaceuticals and SuperGen Inc. overseeing early drug discovery and development. He was the founding Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute as well as an Associate Professor in the Department of Oncological Sciences at the University of Utah and Associate Professor of Physiology & Developmental Biology at Brigham Young University. Dr. Bearss was the founder and CEO of Tolero Pharmaceuticals which he led through its acquisition by Sumitomo DaiNippon Pharma in 2017. He stayed on after the acquisition as CEO of Tolero and as Global head of Research and CSO of SDP Oncology. He is also serving as the Senior Managing Director, UTAH Therapeutics Accelerator at the University of Utah which is focused on helping new therapeutic technologies discovered at the University of Utah transition to clinical development. Dr. Bearss has published more than 80 manuscripts and book chapters, has over 50 patents issued or pending and has won several awards for his scientific achievements.
Prior to joining Xenter, Tony served as Group Chief Financial Officer at Zimmer Biomet where he was responsible for all strategic and financial planning, business development, accounting, and internal controls for over $8B in revenues across all global business units. Additionally, Collins held numerous other financial leadership positions at Zimmer Biomet, including Vice President, Finance, Corporate Controller and Chief Accounting Officer and Vice President Finance for Global Operations and Supply Chain. Prior to Zimmer Biomet, Collins held several executive leadership positions with Guidant/Boston Scientific, including Chief Financial Officer of Guidant Japan.
Scott Texley is the Lead Quality Executive for all of Xenter’s business units. His career spans over 30 years of diverse global experience within the medical/healthcare industry. During his extensive professional career, he has held various executive leadership and transformational management positions within Quality, Regulatory Compliance, Enterprise/Portfolio/Program Management and Marketing. His Medical Device experience spans a diverse set of global markets and therapies including Cardiovascular, Peripheral Interventions, Structural Heart, Neurovascular, Heart Failure, Cardiac Rhythm Management and Electrophysiology. Prior to Xenter, Mr. Texley has held Senior Vice President/Vice President/Leadership positions at Abbott Laboratories, St. Jude Medical (now Abbott), Boston Scientific Corporation and Scimed Life Systems, Inc. (now Boston Scientific).
Mr. Texley has extensive experience in formulating strategic organizational, operational and quality planning – as well as establishing world-class portfolio management systems to effectively drive product development from concept through commercialization. He also has significant experience in M&A activities – leading or assisting in the integration of Quality and Product Development systems/technologies for small, medium and large-cap medical organizations. His specific Medical Device Quality/Regulatory Compliance experience encompasses Device Class I – III, Diagnostic & Therapeutic product classifications, IDE, PMA, 510(k), HDE, Combination Products, CE-Marking within MDD 93/42/EEC, ISO 9001/ISO 13485 QMS, Certification Audits, as well as extensive global regulatory agency interactions.
Mr. Texley holds a Bachelor’s Degree in Industrial Technology/Quality Technology from the University of Wisconsin – Stout, an MBA in Leadership from the University of St. Thomas – Minnesota, and has completed numerous Executive Leadership Programs and Industry Certifications.
Mr. Pearson has a keen interest in the interplay between emerging technologies and the law. Eric’s tech hobbies include coding in Python. From 2003 to 2009, he and a partner built and sold eWatches.com, an ecommerce business specializing in wristwatches. Eric built a cryptocurrency mining rig from scratch. He most likely owns the high score for Galaga at DefCon 27’s arcade party.
Mr. Pearson has served as a founding board member of Team Kid Courage, a non-profit dedicated to helping children with disabilities, participate in sporting and other active events notwithstanding their physical limitations. Eric enjoys spending time with his wife, children and grandchildren, and is an avid skier, marathoner and mountaineer.
Education & Training
University of Sheffield Medical School (UK)
Residency: University of Cambridge (UK)
Doctorate in Philosophy: University of Oxford (UK)
Post-doctoral Fellowship: Stanford University
Residency: Stanford University Medical Center
Fellowship: Stanford University Medical Center
Fellowship: Mount Sinai Medical Center
Honors and Awards
CRF/TCT – Best Coronary Case of TCT 2019
EuroPCR – “PCR’s got Talent” # 1 ranked scientific submission (1stof 1018)
Columbia University Louis V Gerstner Jr. Scholar
CRF/TCT Thomas J Linnemeier Spirit of Interventional Cardiology Runner-up
Best of Basic Science, American Heart Association
Northwestern Cardiovascular Young Investigator 3rd Place
Columbia University Paul Marks Scholar
American Heart Association Young Investigator
(Council on Functional Genomics and Translational Biology)
American Heart Association Peripheral Vascular Disease Award
(Council on Peripheral Vascular Disease)
Stanford Cardiovascular Medicine Outstanding Clinical Fellow Award
Stanford Cardiovascular Institute Gerald M Reaven Award (Basic Science)
Stanford Cardiovascular Institute Young Investigator Award (Basic Science)
American College of Cardiology Young Investigator Award
(Molecular and Cellular Cardiology)
British Atherosclerosis Society/British Society for Cardiovascular Research
Young Investigator Award (Basic Science)
British Cardiovascular Society Young Researcher Award (Clinical Science)
UK Vascular Society Sol Cohen (Founder’s) Young Investigator Award
William R Miller Senior Scholar– St Edmund Hall, University of Oxford
Christ Church College Senior Scholarship
Wellcome Trust Fellowship in Cardiovascular Medicine
University of Sheffield School of Medicine Valedictorian (Gold Medal)- Final MB ChB
Honors and Distinction Final MB ChB
Dr. Mark Gregory Baker (Ashby De La Zouch) Prize in Medicine and Surgery
Glaxo Wellcome Prize in Basic Clinical Sciences
Distinction Genito-urinary, Endocrine, Reproduction, Gastro-intestinal, Liver
Distinction Hematology, Immunology, Genetics, Oncology
University Overseas Scholarship for academic excellence
Ontario Scholar for academic excellence
William Fearon, MD graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Medicine (Cardiology) and Director on Interventional Cardiology at Stanford University School of Medicine and the Chief of the Cardiology Section at the VA Palo Alto Health Care System. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation and the Association of University Cardiologists.
Research areas: Interventional Cardiology Education and Practice, Acute coronary syndromes, Hemodynamics, Hypertrophic Cardiomyopathy
2014 Master, Society of Cardiac Angiography and Intervention
2013 Elite Reviewer, Journal of American College of Cardiology
2012 Elite Reviewer, Cathand Cardiovascular Intervention
2011- ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Cardiologists in Orange County’, peer listing, OC Register
2009 Simon Dack Award, Outstanding Scholarship from the JACC
2008 Southern California ‘Super’ Doctors (Cardiology), Orange Co Mag
1993-2005 Top Doctors in St. Louis (Cardiology), St. Louis Magazine
2004 Elite Reviewer, Journal of American College of Cardiology
1989 Certificate of Proficiency, SCAI
1976 Merck Scholarship Book Award
1975 Alpha Omega Alpha Medical Honor Society
2014-Chief, Medicine Health Care Group, VA Long Beach Health Care System
2009-14 Chief, Division of Cardiology, VA Long Beach Health Care System2006- Associate Chief, Division of Cardiology, University California Irvine
2006- Professor of Medicine, Univ Calif Irvine, Orange, California
2008-2009 Director, Clinical Research, Long Beach Memorial Hospital 2005-2006 Director, Clinical Research, PCA, Costa Mesa, California
2005-2006 Voluntary Clinical Professor of Medicine, Cardiology, USC1991-2004 Professor of Medicine, St. Louis University School of Medicine1989-2004 Director, J.G. Mudd Cardiac Catheterization Lab, St. Louis Univ.1988-1991 Associate Professor of Medicine, SLU
1985-1993 Director Cardiac Cath lab, John Cochran VA , St. Louis
1985-1989 Associate Director, Cardiac Catheterization Laboratory, SLU
1985-1988 Assistant Professor of Medicine, Medicine/Cardiology, SLU
1984-1985 Associate Director, Cardiac Cath Lab. Audie L. Murphy VA UTSA
1982-1985 Assistant Professor of Medicine, Cardiology, Univ Texas HSC, San Antonio, Texas
1981-1982 Junior Associate, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
TRAINING AND FACULTY APPOINTMENTS
Mount Sinai-Icahn School of Medicine
Univ Conn Health Center
Internal Medicine, 1988 – 1991
Mt Sinai Hosp
Cardiovascular Disease, 1991 – 1994
Mt Sinai Hosp
Interventional Cardiology, 1994 – 1995
AWARDS AND CREDENTIALS
Board of trustees — SCAI
Program Committee for the American Heart Association Scientific Sessions
Board of directors — Harboring Hearts
Program Chair for Society of Cardiac Angiography and Interventions (SCAI- WIN (Women in Innovations)) Initiative
Chief Scientific Officer of the Clinical Trials Center at the Cardiovascular Research Foundation
Dr. Mintz completed his undergraduate education at the University of Pennsylvania in 1970 and received his medical degree from Hahnemann University in 1974, both in Philadelphia, PA. He finished his internship in 1975, residency in 1976, and cardiology fellowship in 1978, each at Hahnemann University. He joined the Hahnemann University Department of Medicine in 1978 and was promoted to Professor of Medicine in 1987 before joining CRF in 1991. His administrative appointments there included Director of the Cardiac Ultrasound Laboratory, Director of the Coronary Care Unit, and Director of the Cardiology Fellowship Training Program. He received teaching awards from both the Department of Medicine Residency and Cardiology Fellowship Training Programs.
Honors & Awards
Research Fellowship Award, Southern Pennsylvania Heart Assoc. 1978-1980
Member, PTCA Subcommittee NHLBI-Study of Thrombolysis in
Acute Myocardial Infarction (TIMI) 1986-1987
Consultant: FDA Committee on Biologics 1986
Chairman: New York Angioplasty Society 1987-1988
Lectureship, Sendai Medical College, Tohoku Medical Society,
Sendai, Japan 1990
Lectureship, The Vivian & Norman Weiden Lecture: Innovative
Approaches to Coronary Artery Disease 1996
New York Cardiological Society, NYC
Listed in Best Doctors of the Year, New York Magazine 2004-2016
America’s Top Doctors –Castle Connolly 2005-2016
Lifetime Achievement Award, Cardiovascular Research Foundation 2006
C3 Lifetime Career Achievement Award-C3 Hall of Fame 2010
Varinder Singh, MD, is responsible for the quality and delivery of cardiovascular care at Lenox Hill Hospital and Northwell Health’s Western Region. As chair, Dr. Singh has played an integral role in reestablishing Lenox Hill as a leading center for cardiovascular medicine in Manhattan.
Dr. Singh is secretary of the Lenox Hill Medical Board and a member of the hospital’s Credentials Committee and International Services Committee. He is an assistant professor of cardiology at the Zucker School of Medicine, and his professional memberships include the American College of Cardiology, Society of Cardiovascular Angiography and Interventions, Bronx Medical Society and New York Medical Society.
Gregg W. Stone is Professor of Medicine at the Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 80 national and international multicenter randomized trials, has authored more than 2000 book chapters, manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. Dr. Stone’s areas of expertise include interventional therapies of acute coronary syndromes and myocardial infarction; drug-eluting stents; antiplatelet and antithrombotic pharmacotherapies; transcatheter mitral valve repair and replacement; new device angioplasty including atherectomy, distal embolic protection, thrombectomy, vascular brachytherapy, and stent grafts; saphenous vein graft therapies; intravascular imaging; chronic total occlusions; left atrial appendage closure; vulnerable plaque; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone, along with Dr. Martin B. Leon, is the director of Transcatheter Cardiovascular Therapeutics (TCT), the world’s largest symposium devoted to interventional cardiology and vascular medicine, directs the annual National Interventional Cardiology Fellow’s Course, and co-directs multiple other annual courses, including Optimizing Complex PCI Outcomes, The Left Main and Chronic Total Occlusion Summit, Bioresorbable Scaffolds: A Breakthrough PCI Technology, LAA Occlusion: A Technique Oriented Course, and Transcatheter Valve Therapies. Dr. Stone’s medical practice is devoted to interventional cardiology at New York-Presbyterian Hospital and Columbia University Medical Center.